Mendelian randomization reveals potential causal candidates for COVID-19 in 123 blood metabolites

We read with interest the recently published letter in Journal of Infection by Dr. Yang et al., who conducted a quantitative meta-analysis of twenty-seven studies containing 146,364 cases and found a lack of association between dyslipidemia and COVID-19 mortality (1). However, Dr. Hilser et al. investigated the relationship between metabolic syndrome-related serum biomarkers and the severity of COVID-19 in UK Biobank and found that an increase of 10 mg/dl HDL-Cholesterol reduced the risk of suffering from COVID-19 by 13% (OR  = 0.87, 95% CI: 0.79–0.94, P = 1.2E-03) (2).
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research